Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran
Journal of the American Heart Association · 19.03.2024 · 13 (6)
DOI: 10.1161/jaha.123.032031 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the American Heart Association, erschienen am 19.03.2024. Verfasst von Michael J Wilkinson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Medicine Cardiovascular Institute, University of California San Diego San Diego CA USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Anticholesteremic Agents. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Lowering low‐density lipoprotein cholesterol (LDL‐C) is a cornerstone of reducing risk for atherosclerotic cardiovascular disease. Despite the approval of nonstatin therapies for LDL‐C lowering over the past 2 decades, these medications are underused, and most patients are still not at guideline‐recommended LDL‐C goals. Barriers include poor adherence, clinical inertia, concern for side effects, cost, and complex prior authorization processes. With atherosclerotic cardiovascular disease‐related mortality increasing globally, there remains a need for additional therapeutic options for lowering LDL‐C as part of an atherosclerotic cardiovascular disease prevention strategy. Following the identification of PCSK9 (proprotein convertase subtilisin/kexin type 9) as a promising therapeutic target, inclisiran was developed using the natural process of RNA interference for robust, sustained prevention of hepatic PCSK9 synthesis. Twice‐yearly maintenance subcutaneous inclisiran (following initial loading doses at Day 1 and Day 90) reduces circulating LDL‐C levels by ≈50% versus placebo when added to maximally tolerated statins. Long‐term safety and tolerability of inclisiran have been assessed, with studies underway to evaluate the effects of inclisiran on cardiovascular outcomes and to provide additional safety and effectiveness data. In 2021,
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Department of Medicine Cardiovascular Institute, University of California San Diego San Diego CA USA.
- Department of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia PA USA.
- Cardiovascular and Metabolism Disease Area, Novartis Institutes for BioMedical Research Cambridge MA USA.
ORCID-Profile: Michael J Wilkinson, Archna Bajaj, Pam R Taub
Zitieren
APA
Wilkinson, M. J., Bajaj, A., Brousseau, M. E., & Taub, P. R. (2024). Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran. Journal of the American Heart Association, 13(6). https://doi.org/10.1161/jaha.123.032031
Vancouver
Wilkinson MJ, Bajaj A, Brousseau ME, Taub PR. Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran. Journal of the American Heart Association. 2024;13(6). doi:10.1161/jaha.123.032031
BibTeX
@article{Wilkinson2024,
author = {Wilkinson, Michael J and Bajaj, Archna and Brousseau, Margaret E and Taub, Pam R},
title = {Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran},
journal = {Journal of the American Heart Association},
year = {2024},
volume = {13},
number = {6},
doi = {10.1161/jaha.123.032031}
}
EUVIMED